Date | Price Target | Rating | Analyst |
---|---|---|---|
3/11/2024 | $5.00 | Buy | H.C. Wainwright |
8/21/2023 | $3.00 | Buy | Lake Street |
10/21/2022 | $5.00 | Buy | Jefferies |
4 - OptiNose, Inc. (0001494650) (Issuer)
4 - OptiNose, Inc. (0001494650) (Issuer)
4 - OptiNose, Inc. (0001494650) (Issuer)
YARDLEY, Pa., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will report financial results for the second quarter 2024 and corporate updates, before market open, on Thursday, August 8, 2024. Company to Host Conference CallMembers of the Company's leadership team will host a conference call to discuss financial results and corporate updates. The call is scheduled to start at 8:00 a.m. Eastern Time on Thursday, August 8, 2024. Participants may access the conference call live via webcast by visiting the Investors section of Optinose's website at
YARDLEY, Pa., May 10, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will report financial results for the first quarter 2024 and corporate updates, before market open, on Tuesday, May 14, 2024. Company to Host Conference CallMembers of the Company's leadership team will host a conference call to discuss financial results and corporate updates. The call is scheduled to start at 10:00 a.m. Eastern Time on Tuesday, May 14, 2024. Participants may access the conference call live via webcast by visiting the Investors section of Optinose's website at http://
YARDLEY, Pa., April 25, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced corporate updates detailing its commercial plans and expectations for XHANCE® (fluticasone propionate) following the recent FDA approval of a new indication for the treatment of chronic rhinosinusitis without nasal polyps in patients 18 year of age and older. The Company will host an investor call at 10:00 a.m. Eastern Time today to discuss its commercial strategy and financial outlook. In addition, the Company announced preliminary XHANCE net product revenue of $14.9 million for the three mon
H.C. Wainwright initiated coverage of OptiNose with a rating of Buy and set a new price target of $5.00
Lake Street initiated coverage of OptiNose with a rating of Buy and set a new price target of $3.00
Jefferies resumed coverage of OptiNose with a rating of Buy and set a new price target of $5.00
YARDLEY, Pa., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Peter Miller has stepped down as Chief Executive Officer and Board member, and that Ramy Mahmoud, MD, MPH has been appointed as Chief Executive Officer and Board member. In announcing his departure, Peter Miller shared, "It has been a privilege working with the amazing group of colleagues at Optinose. I am proud of all that we have accomplished and the impact we continue to make in our mission to improve patients' lives." During Mr. Miller's nearly 13 years as CEO, the Company experienced s
YARDLEY, Pa., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the appointment of Paul Spence as Chief Commercial Officer. Mr. Spence was most recently the Senior Vice President of the U.S. Commercial Organization at Nestlé Health Sciences where he built the commercial capabilities for the Aimmune Gastrointestinal and Food Allergy businesses. Mr. Spence has 30 years of experience in the life science and pharmaceuticals industry as a leader responsible for marketing, sales, market access, operations, and supply chain. Prior to joining Nestlé Health Sciences,
YARDLEY, Pa., April 26, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that it has appointed R. John Fletcher to its Board of Directors as a Class III director. "We are pleased to welcome John to the Optinose Board of Directors," stated Joe Scodari, Chairman of the Optinose Board of Directors. "His extensive experience with healthcare and medical devices, as well as his more than 30 years of strategy and financing experience across the pharmaceutical and healthcare industry, make him an exceptional candidate to join our Board. Optinose values the input of its stock
SC 13G/A - OptiNose, Inc. (0001494650) (Subject)
SC 13G/A - OptiNose, Inc. (0001494650) (Subject)
SC 13G/A - OptiNose, Inc. (0001494650) (Subject)
10-Q - OptiNose, Inc. (0001494650) (Filer)
8-K - OptiNose, Inc. (0001494650) (Filer)
8-K - OptiNose, Inc. (0001494650) (Filer)
YARDLEY, Pa., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the peer-review publication of a paper titled, "EDS-FLU efficacy in patients with chronic rhinosinusitis with or without prior sinus surgery in ReOpen1 and ReOpen2 randomized controlled trials"1 in the International Forum of Allergy & Rhinology, the journal of the American Rhinologic Society. As discussed in the publication, the inability of topical medications to reach the region of the sinus cavities is a potential reason for lack of efficacy in chronic rhinosinusitis (CRS), particularly the c
YARDLEY, Pa., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the H.C. Wainwright 26th Annual Global Investment Conference on September 9, 2024 at 10:00 a.m. ET. To listen to a webcast of the presentation live, please visit the Investors page of the Optinose website. A replay of the webcast will be available for 30 days following the conclusion of the event. About OptinoseOptinose is a specialty pharmaceutical company focused on serving the needs of patients cared f
Company reports Q2 2024 XHANCE net revenue of $20.5 million, an increase of 5% compared to Q2 2023 XHANCE has been added to Express Scripts' national formularies, among the largest commercial formularies in the U.S. with more than 24 million lives Company narrows full year 2024 XHANCE net revenue guidance to be between $85.0 to $90.0 million and increases expected average net revenue per prescription guidance to be at least $250 Conference call and webcast to be held today at 8:00 a.m. Eastern Time YARDLEY, Pa., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today re
Shares of Doximity, Inc. (NYSE:DOCS) rose sharply in today's pre-market trading reported stronger-than-expected financial results for the fourth quarter on Thursday. Doximity's fourth-quarter revenue increased 6% year-over-year to $118.1 million, which beat the consensus estimate of $116.4 million, according to Benzinga Pro. The company reported adjusted earnings of 25 cents per share, beating analyst estimates of 20 cents per share. The company said it expects first-quarter revenue to be between $119.5 million and $120.5 million versus estimates of $119.23 million. Doximity shares jumped 13.7% to $27.00 in the pre-market trading session. Here are some other stocks moving in pre-
Gainers Scorpius Holdings (AMEX:SCPX) shares rose 20.9% to $0.12 during Thursday's after-market session. The market value of their outstanding shares is at $4.3 million. Kintara Therapeutics (NASDAQ:KTRA) stock increased by 19.22% to $0.17. The company's market cap stands at $6.7 million. The company's, Q3 earnings came out 2 days ago. Doximity (NYSE:DOCS) stock rose 11.4% to $26.45. The market value of their outstanding shares is at $4.9 billion. As per the news, the Q4 earnings report came out today. MEI Pharma (NASDAQ:MEIP) stock increased by 10.92% to $3.25. The company's market cap stands at $21.6 million. Akso Health Group (NASDAQ:AHG) stock increased by 9.36% to $0.69. The compan